Shinya Ueda

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology · 2013 · 559 citations

Medicine, Oncology, Pharmacology +10

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 282 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 219 citations

Medicine, Oncology, Pharmacology +7

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

Taroh Satoh, Isamu Okamoto, Masaki Miyazaki et al. · Clinical Cancer Research · 2009 · 176 citations

Medicine, Oncology, Pharmacology +17

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

Makoto Tahara, Naomi Kiyota, Tomoya Yokota et al. · Annals of Oncology · 2018 · 97 citations · Full text

Medicine, Oncology, Pharmacology +13